| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
232,140,000 |
| Market
Cap: |
1.80(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.23 - $9.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ardelyx is a biopharmaceutical company focused on discovering, developing and commercializing medicines. This includes adult patients with irritable bowel syndrome with constipation (IBS-C), adult patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and adult patients with CKD and/or heart failure with elevated serum potassium, or hyperkalemia. Co.'s product pipeline includes among other, IBSRELA, a sodium hydrogen exchanger 3 inhibitor for the treatment of IBS-C in adults; and XPHOZAH, which is a medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
585,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,011,778 |
| Total People Bought |
0 |
0 |
0 |
7 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
766,409 |
1,189,266 |
1,315,394 |
1,951,649 |
| Total Sell Value |
$6,577,948 |
$9,083,370 |
$9,535,666 |
$10,165,404 |
| Total People Sold |
8 |
8 |
8 |
8 |
| Total Sell Transactions |
18 |
37 |
59 |
102 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rosenbaum David P. |
Chief Development Officer |
• – – |
2024-01-08 |
4 |
AS |
$6.64 |
$199,200 |
D/D |
(30,000) |
286,596 |
|
-5% |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2023-12-26 |
4 |
AS |
$6.36 |
$1,430,123 |
D/D |
(225,000) |
182,426 |
|
44% |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2023-12-26 |
4 |
OE |
$0.99 |
$74,250 |
D/D |
75,000 |
407,426 |
|
- |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2023-12-18 |
4 |
AS |
$6.07 |
$34,447 |
D/D |
(5,675) |
316,596 |
|
2% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2023-12-14 |
4 |
AS |
$5.55 |
$38,850 |
D/D |
(7,000) |
322,271 |
|
11% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2023-12-11 |
4 |
AS |
$5.08 |
$253,925 |
D/D |
(50,000) |
275,675 |
|
23% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2023-12-08 |
4 |
AS |
$5.27 |
$105,476 |
D/D |
(20,000) |
329,271 |
|
24% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2023-12-05 |
4 |
AS |
$5.00 |
$51,360 |
D/D |
(10,272) |
349,271 |
|
34% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2023-11-30 |
4 |
AS |
$4.50 |
$13,500 |
D/D |
(3,000) |
359,543 |
|
63% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2023-11-20 |
4 |
S |
$4.36 |
$4,066 |
I/I |
(932) |
113,293 |
|
-68% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2023-11-20 |
4 |
S |
$4.36 |
$12,367 |
D/D |
(2,835) |
362,543 |
|
-68% |
|
| Rodriguez Susan |
Chief Commercial Officer |
• – – |
2023-11-20 |
4 |
S |
$4.36 |
$20,563 |
D/D |
(4,714) |
346,973 |
|
-68% |
|
| Williams Laura A |
Chief Medical Officer |
• – – |
2023-11-20 |
4 |
S |
$4.36 |
$11,259 |
D/D |
(2,581) |
266,191 |
|
-68% |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2023-11-20 |
4 |
S |
$4.36 |
$12,533 |
D/D |
(2,873) |
332,426 |
|
-68% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2023-11-20 |
4 |
S |
$4.36 |
$10,399 |
D/D |
(2,384) |
325,675 |
|
-68% |
|
| Raab Michael |
President & CEO |
• • – |
2023-11-20 |
4 |
S |
$4.36 |
$49,589 |
D/D |
(11,368) |
867,868 |
|
-68% |
|
| Blanks Robert |
See Remarks |
• – – |
2023-11-20 |
4 |
S |
$4.36 |
$12,367 |
D/D |
(2,835) |
260,453 |
|
-68% |
|
| Felsch Robert Ora |
See Remarks |
• – – |
2023-11-20 |
4 |
S |
$4.36 |
$4,554 |
D/D |
(1,044) |
117,066 |
|
-68% |
|
| Williams Laura A |
Chief Medical Officer |
• – – |
2023-11-15 |
4 |
S |
$4.00 |
$99,998 |
D/D |
(25,000) |
266,839 |
|
-91% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2023-10-10 |
4 |
AS |
$4.00 |
$6,576 |
D/D |
(1,644) |
365,378 |
|
107% |
|
| Rosenbaum David P. |
Chief Development Officer |
• • – |
2023-09-08 |
4 |
AS |
$4.55 |
$13,181 |
D/D |
(2,897) |
367,022 |
|
75% |
|
| Williams Laura A |
Chief Medical Officer |
• – – |
2023-08-21 |
4 |
S |
$3.55 |
$9,203 |
D/D |
(2,591) |
291,839 |
|
-79% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2023-08-21 |
4 |
S |
$3.55 |
$8,496 |
D/D |
(2,392) |
328,059 |
|
-79% |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2023-08-21 |
4 |
S |
$3.55 |
$10,243 |
D/D |
(2,884) |
333,849 |
|
-79% |
|
| Rodriguez Susan |
Chief Commercial Officer |
• – – |
2023-08-21 |
4 |
S |
$3.55 |
$16,811 |
D/D |
(4,733) |
348,687 |
|
-79% |
|
538 Records found
|
|
Page 2 of 22 |
|
|
0.29 (3.6%) 
